Stockholm:RHOVAC

Positive Results from RhoVac's Clinical Phase I/II Study published in Journal of ImmunoTherapy of Cancer

STOCKHOLM, Nov. 13, 2020 /PRNewswire/ -- RhoVac announces today, November 13, 2020, that the results of its clinical phase I/II study have been published in the Journal for ImmunoTherapy of Cancer (JITC). The scientifically reviewed article reports that the treatment with RhoVac's drug candidate ...

2020-11-13 17:53 1242

First patient in treatment in RhoVac's clinical phase IIb study in Sweden

STOCKHOLM, Sept. 17, 2020 /PRNewswire/ --  RhoVac AB ("RhoVac") announces today, onSeptember 17 2020, that the first patient in Sweden is enrolled in the company's clinical phase IIb study in prostate cancer, a study named RhoVac-002 ("BRaVac"). The first patient in Sweden is enrolled in the cli...

2020-09-17 23:51 2666

RhoVac appoints Professor Georg Hollaender to its Scientific Advisory Board

STOCKHOLM, Sept. 4, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today September 4th 2020,  that it is continuing to strengthen the Scientific Advisory Board with a pediatric immunologist, by appointing ProfessorGeorg Hollaender, Action Research Professor and Head of Department at Oxford ...

2020-09-04 17:35 3023

First Patient in Treatment in RhoVac's Clinical Phase IIb Study in Germany

STOCKHOLM, April 24, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") announces today, on 23rd April 2020, that the first patient in Germany is in treatment in the company's clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 ("BRaVac"). The first patient in Germany is in treatment...

2020-04-24 00:37 1224